Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Pharmaceutics|September 28, 2021
Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In VitroLinda Brunotte, Shuyu Zheng, Angeles Mecate-Zambrano, et al.
Emerging Microbes & Infections|September 25, 2020
Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetineSebastian Schloer, Linda Brunotte, Jonas Goretzko, et al.
Pharmacological Research|May 12, 2025
The host cell factor DDX3 mediates sex dimorphism in the IFNα response of plasmacytoid dendritic cells upon TLR activationSebastian Schloer, Jana Hennesen, Lena Rueschpler, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 10, 2019
The annexin A1/FPR2 signaling axis expands alveolar macrophages, limits viral replication, and attenuates pathogenesis in the murine influenza A virus infection modelSebastian Schloer, Nicole Hübel, Dörthe Masemann, et al.
Frontiers in Immunology|October 17, 2018
Phosphorylation of TRIM28 Enhances the Expression of IFN-β and Proinflammatory Cytokines During HPAIV Infection of Human Lung Epithelial CellsTim Krischuns, Franziska Günl, Lea Henschel, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 7, 2026
Acid sphingomyelinase is an age-dependent host cell factor for adenovirus entry and a pharmacological target for synergistic combination therapy with brincidofovirSophie Post, Mohamed Zamzamy, Luca Benthien, et al.
International Journal of Molecular Sciences|November 11, 2022
Immunothrombotic Mechanisms Induced by Ingenol Mebutate Lead to Rapid Necrosis and Clearance of Anogenital WartsStephan A Braun, Alexander T Bauer, Csongor Németh, et al.
Emerging Microbes & Infections|August 24, 2022
3D <i>Ex vivo</i> tissue platforms to investigate the early phases of influenza a virus- and SARS-CoV-2-induced respiratory diseasesSebastian Schloer, Daniel Treuherz, Aileen Faist, et al.
Cellular and Molecular Life Sciences : CMLS|January 11, 2022
The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responsesAndré Schreiber, Dorothee Viemann, Jennifer Schöning, et al.
British Journal of Pharmacology|November 28, 2025
Synergistic antiviral activity against human adenovirus through combination of itraconazole and brincidofovirMohamed Zamzamy, Sophie Post, Wing Hang Ip, et al.
Pageof 3